Earth Science Tech Inc (OTCMKTS:ETST) reported the up of 5.24% and closed at $2.04, with the total traded volume of 23,859.00 million shares. During last trade its minimum price was $111,291.00 and it gained its highest price of $2.09 and has a total of 40.91 million outstanding shares.
On February 16, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals, announces it has successfully formulated and is preparing to launch a new High Grade Hemp CBD (Canabidiol) Oil formulated for domestic animals (pets), which will give the company a firm footing in the $60B pet industry.
Across the world, CBD-based pet products are seeing heightened demand. Trial studies have shown that CBD oils help reduce anxiety, inflammation, and chronic pain, while bolstering the immune system in pets. Results, have demonstrated rapid results in aiding and alleviating pets in the previously mentioned ailments, which is one of the mere reasons pet owners are eager in obtaining scientifically proven CBD wellness products from reputable and trustworthy companies.
Currently, ETST is in the process of bottling and packaging its newly developed and anticipated Nutraceutical Scientific “High Grade Hemp Pet CBD Oil” formulation (strawberry flavored), which launch date is projected late in the first quarter of the fiscal year 2017. ETST is maximizing its profitability by gaining its competitive advantage in a growing market by creating and developing a product that is not only in high demand, but that will revolutionize the ever growing market that is the pet industry. As further research and development on the benefits of “High Grade Hemp Pet CBD Oil” is conducted and a myriad of additional benefits are discovered there is no doubt that this niche market provides an opportunity to enhance and enrich the lives of pets and consequently their owners, given the fact that there are 70-80 million dogs and 74-96 million cats owned in the United States alone as per the ASPCA. View ETST’s High Grade Hemp Pet CBD product, (http://earthsciencetech.com/product/new-1-ounce-strawberry-unfiltered-high-grade-hemp-pet-cbd-250mg-cbd-oil/).
GW Pharmaceuticals (NASDAQ:GWPH) showing dropped of -0.50% and closed at $122.47, after gaining total volume of 202,950.00 shares. Its earnings per share (EPS) is -$3.26 and its beta value stands at 2.66 points and has total market capitalization of $2.82 billion and a total of 302.46 million outstanding shares.
GW Pharmaceuticals (GWPH) on March 7, 2017 announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer Justin Gover, Mr. Giacobello will be based at the Company’s U.S. headquarters in Carlsbad, California. Related to this appointment, on 6 March 2017 Adam George, GW’s Chief Financial Officer since 2012, became Managing Director – UK, a newly-created executive role with broad leadership responsibilities for UK operations, also reporting to Justin Gover.
“These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company. In anticipation of Epidiolex approval and launch, and with GW now solely listed on Nasdaq, we expect to transition from being a Foreign Private Issuer reporting under IFRS to become a domestic registrant reporting under USGAAP and in US dollars in future years. Scott’s significant financial and accounting expertise will be a major asset to the organization as we make that shift,” stated Justin Gover, GW’s Chief Executive Officer. “In addition, with Adam having served as CFO since 2012, his new Managing Director – UK role leverages the broad knowledge he has of our business and provides continuity of strong senior UK-based leadership, essential elements to our continued success.”
Scott Giacobello brings 25 years of finance and operational experience to GW Pharmaceuticals. He is an accomplished executive who most recently and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Mr. Giacobello’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.
Insys Therapeutics (NASDAQ:INSY) increased 2.91% closed at $10.26 and traded with total volume of 536,927.00 shares, while the average trading remained 1.13M million shares. During last trade its minimum price was $9.92 and it gained the highest price of $10.37. Its market capitalization was $729.77 million.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.